普門科技(688389.SH)：2020年淨利升43.15%至1.44億元 擬10派1.78元
格隆匯3月19日丨普門科技(688389.SH)披露2020年年度報吿，報吿期內，公司實現營業收入5.54億元，同比增長31.04%；歸屬於母公司股東的淨利潤1.44億元，同比增長43.15%；歸屬於上市公司股東的扣除非經常性損益的淨利潤1.23億元，同比增長44.72%；基本每股收益0.34元，年報推10派1.78元(含税)。
公司是一家研發和市場雙輪驅動的專業化高科技醫療設備企業，主要從事醫療器械的研發、製造、營銷及服務，專注於治療與康復設備和體外診斷設備和配套檢測試劑的開發及技術創新。公司堅持以技術創新為根基，以臨牀診療需求為導向，提高自主創新能力，增強產品核心競爭力，持續推出對人類健康和生命有顯著價值的產品和服務。
在治療與康復領域，公司產品主要圍繞三大服務領域進行產品開發，包括創面和皮膚治療、圍手術期和重症護理、疼痛和康復治療，現有產品包括多功能清創儀、光子治療儀、負壓引流套裝、高頻振動排痰儀、空氣壓力波治療系統、高流量呼吸濕化器、醫用升温毯、紅外治療儀、脈衝磁治療儀、中頻干擾電治療儀、衝擊波治療儀等，公司通過技術創新、產品研發、升級換代和專業服務等方式，針對不同疾病、不同科室的相應需求推出適宜的產品組合方案，有效促進疾病治療與康復的臨牀療效。
在體外診斷領域，公司基於電化學發光、免疫比濁、液相色譜、免疫熒光、血凝力學測試、分子診斷六大技術平台，為醫院、體檢中心提供一系列全自動及半自動的體外診斷產品，主要包括全自動電化學發光免疫測定儀、特定蛋白分析儀、糖化血紅蛋白分析儀、自動尿液微量白蛋白肌酐分析儀、乾式熒光分析儀等及相關配套試劑，通過對人體的樣本(如血液、體液、組織等)的檢測而獲取臨牀診斷信息。
目前，公司產品及解決方案覆蓋國內1萬5千多家醫療機構，裝機醫院包括國內知名的中國人民解放軍總醫院(301醫院)、中國人民解放軍總醫院第一附屬醫院、華中科技大學附屬同濟醫院、中南大學附屬湘雅醫院、廣東省中醫院、四川大學華西醫院、中國醫科大學附屬第一醫院等在內的1,600餘家三級醫院。在國際市場，公司產品已應用於全球80多個國家和地區，成功覆蓋歐洲、亞洲、南美洲、中東及非洲等市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
